Longitudinal ctDNA tracking in early and recurrent breast cancer using an ultrasensitive structural variant-based assay: an extended analysis from the TRACER study.

M J Elliott¹, J Roh², T Bird², M Li², M B Nadler², E Amir², V Kumar², C Yu³, M Alcaide⁴, S Birkeälv⁴, V Hafstad⁴, E Gray⁴, E C de Bruin⁵, W Levin⁴, L L Siu², P L Bedard², H K Berman⁶, K Howarth⁴, D W Cescon²

¹Division of Medical Oncology & Hematology, Department of Medicine, Princess Margaret Cancer Centre and University of Toronto, Toronto, Canada; Yale University (School of Medicine), Yale Cancer Center, New Haven, USA. Electronic address: Mitchell.Elliott@uhn.ca.

²Division of Medical Oncology & Hematology, Department of Medicine, Princess Margaret Cancer Centre and University of Toronto, Toronto, Canada.

³Cancer Genomics Program, Princess Margaret Cancer Centre, Toronto, Canada.

⁴Foundation Medicine, Inc., Boston, USA.

⁵Oncology R and D, AstraZeneca, Cambridge, UK.

⁶Department of Pathology and Laboratory Medicine, University Health Network, Toronto, Canada.

PubMed DOI

Abstract

BACKGROUND: Detection of circulating tumor DNA (ctDNA) following curative-intent therapy is prognostic of disease recurrence in early-stage breast cancer (EBC). An ultrasensitive structural variant (SV)-based ctDNA assay was evaluated previously in a 100-patient EBC cohort treated with neoadjuvant therapy, demonstrating high sensitivity, specificity, and a long lead-time to relapse. The stability…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.